Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.53 |
| ▸ | AR | P10275 | 2/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.53 |
| ▸ | CYP19A1 | P11511 | 5/20 | 0.51 |
| ▸ | RAB9A | P51151 | 6/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.50 |
| ▸ | LMNA | P02545 | 3/20 | 0.50 |
| ▸ | NPC1 | O15118 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | MAPT | P10636 | 2/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.48 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.46 |
| ▸ | SREBF2 | Q12772 | 1/20 | 0.45 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.43 |
| ▸ | CDK5 | Q00535 | 2/20 | 0.42 |
| ▸ | CDK5R1 | Q15078 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1821128 | 0.88 | ALDH1A1 (0.54) | KDM4EARKMT2ACYP19A1RAB9A | |
| SCHEMBL1818589 | 0.85 | RAB9A (0.55) | KDM4EARKMT2ARAB9ASMN1; SMN2 | |
| SCHEMBL207818 | 0.84 | CYP19A1 (0.64) | KDM4ECYP19A1RAB9ANPC1ALDH1A1 | |
| SCHEMBL29654019 | 0.79 | HSP90AA1 (0.46) | CYP19A1RAB9AALDH1A1SREBF2CYP1A1 | |
| SCHEMBL1822088 | 0.79 | KDM4E (0.61) | KDM4EKMT2ACYP19A1RAB9ASMN1; SMN2 | |
| SCHEMBL207728 | 0.78 | CYP19A1 (0.59) | KDM4EARKMT2ACYP19A1RAB9A | |
| SCHEMBL1883277 | 0.77 | IMPDH2 (0.51) | KDM4EKMT2ACYP19A1RAB9ASMN1; SMN2 | |
| SCHEMBL7476653 | 0.75 | ABL1 (0.48) | KMT2ACYP19A1RAB9ALMNANPC1 | |
| SCHEMBL1820141 | 0.75 | C1S (0.49) | KDM4EKMT2ACYP19A1RAB9ASMN1; SMN2 | |
| SCHEMBL11152023 | 0.74 | RAB9A (0.58) | KDM4EARKMT2ARAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2637658-A1 | COMPOSITIONS AND METHODS RELATING TO HEAT SHOCK TRANSCRIPTION FACTOR ACTIVATING COMPOUNDS AND TARGETS THEREOF | Duke University (US) | 2013-09-18 | — | — | EP | claimed |
| WO-2012064715-A1 | COMPOSITIONS AND METHODS RELATING TO HEAT SHOCK TRANSCRIPTION FACTOR ACTIVATING COMPOUNDS AND TARGETS THEREOF | DUKE UNIVERSITY (US) | 2012-05-18 | — | — | WO | claimed |
| US-20110112073-A1 | COMPOSITIONS AND METHODS RELATING TO HEAT SHOCK TRANSCRIPTION FACTOR ACTIVATING COMPOUNDS AND TARGETS THEREOF | DUKE UNIVERSITY (US) | 2011-05-12 | — | — | US | claimed |
| US-20110105436-A1 | HETEROARYL COMPOUNDS, COMPOSITIONS, AND METHODS OF USE IN CANCER TREATMENT | AUCKLAND UNISERVICES LIMITED (NZ) | 2011-05-05 | — | — | US | claimed |
| EP-2637658-A1 | COMPOSITIONS AND METHODS RELATING TO HEAT SHOCK TRANSCRIPTION FACTOR ACTIVATING COMPOUNDS AND TARGETS THEREOF | Duke University (US) | 2013-09-18 | — | — | EP | disclosed |
| WO-2012064715-A1 | COMPOSITIONS AND METHODS RELATING TO HEAT SHOCK TRANSCRIPTION FACTOR ACTIVATING COMPOUNDS AND TARGETS THEREOF | DUKE UNIVERSITY (US) | 2012-05-18 | — | — | WO | disclosed |
| US-20110112073-A1 | COMPOSITIONS AND METHODS RELATING TO HEAT SHOCK TRANSCRIPTION FACTOR ACTIVATING COMPOUNDS AND TARGETS THEREOF | DUKE UNIVERSITY (US) | 2011-05-12 | — | — | US | disclosed |
| US-20110105436-A1 | HETEROARYL COMPOUNDS, COMPOSITIONS, AND METHODS OF USE IN CANCER TREATMENT | AUCKLAND UNISERVICES LIMITED (NZ) | 2011-05-05 | — | — | US | disclosed |
| WO-2009114552-A1 | HETEROARYL COMPOUNDS, COMPOSITIONS, AND METHODS OF USE IN CANCER TREATMENT | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2009-09-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110105436-A1 | HETEROARYL COMPOUNDS, COMPOSITIONS, AND METHODS OF USE IN CANCER TREATMENT | VHL, TP53, BECN1 | KDM4E 2441/4885AR 3835/4885KMT2A 2132/4885 |
| US-20110112073-A1 | COMPOSITIONS AND METHODS RELATING TO HEAT SHOCK TRANSCRIPTION FACTOR ACTIVATING COMPOUNDS AND TARGETS THEREOF | HSF1, HSP90AB1, HSPBP1 | KDM4E 3602/4885AR 1181/4885KMT2A 3757/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.